Literature DB >> 34387699

[Current preoperative and perioperative concepts in tumor treatment for locally advanced esophageal carcinoma from a surgical perspective].

Jens Hoeppner1.   

Abstract

Locally advanced esophageal cancer is mostly treated in multimodal therapy protocols according to the current western treatment guidelines. In squamous cell cancer, neoadjuvant chemoradiotherapy is in the foreground. Unimodal surgical and chemoradiation treatment alternatives achieve poorer results for this entity. Surgical salvage resection for tumor recurrence after definitive chemoradiotherapy can be carried out with good oncological results but the frequency of postoperative complications is increased. For locally advanced adenocarcinoma of the esophagus, perioperative chemotherapy and neoadjuvant chemoradiotherapy are two competing level 1 evidence-based treatment concepts that are superior to treatment by surgery alone. The results of head-to-head comparative treatment studies are still pending. A significant number of patients show a complete locoregional remission of the tumor in the surgical specimen after treatment with the modern neoadjuvant protocols. Currently, European prospective randomized noninferiority studies with an oncological endpoint are testing the possibilities of organ-retaining concepts in clinical complete remission (surgery as needed; watch and wait). For the future, it is to be expected that the curative treatment results of locally advanced esophageal carcinoma will again significantly improve, in particular through the additional possibilities of immunotherapy and organ-preserving therapy concepts for postneoadjuvant complete remission.
© 2021. Springer Medizin Verlag GmbH, ein Teil von Springer Nature.

Entities:  

Keywords:  Chemoradiotherapy; Chemotherapy; Multimodal therapy; Neoadjuvant protocol; Organ-retaining treatment protocol

Mesh:

Year:  2021        PMID: 34387699     DOI: 10.1007/s00104-021-01475-w

Source DB:  PubMed          Journal:  Chirurg        ISSN: 0009-4722            Impact factor:   0.955


  6 in total

1.  KEYNOTE-585: Phase III study of perioperative chemotherapy with or without pembrolizumab for gastric cancer.

Authors:  Yung-Jue Bang; Eric Van Cutsem; Charles S Fuchs; Atsushi Ohtsu; Josep Tabernero; David H Ilson; Woo Jin Hyung; Vivian E Strong; Thorsten Oliver Goetze; Takaki Yoshikawa; Laura H Tang; Peggy May Tan Hwang; Nancy Webb; David Adelberg; Kohei Shitara
Journal:  Future Oncol       Date:  2019-02-19       Impact factor: 3.404

2.  Definitive Chemoradiotherapy Compared to Neoadjuvant Chemoradiotherapy With Esophagectomy for Locoregional Esophageal Cancer: National Population-based Cohort Study.

Authors:  Sivesh K Kamarajah; Alexander W Phillips; George B Hanna; Donald Low; Sheraz R Markar
Journal:  Ann Surg       Date:  2022-03-01       Impact factor: 12.969

Review 3.  Laparoscopic versus open gastrectomy for gastric cancer.

Authors:  Lawrence M J Best; Muntzer Mughal; Kurinchi Selvan Gurusamy
Journal:  Cochrane Database Syst Rev       Date:  2016-03-31

4.  Multimodal treatment of locally advanced esophageal adenocarcinoma: which regimen should we choose? Outcome analysis of perioperative chemotherapy versus neoadjuvant chemoradiation in 105 patients.

Authors:  Jens Hoeppner; Katja Zirlik; Thomas Brunner; Peter Bronsert; Birte Kulemann; Olivia Sick; Goran Marjanovic; Ulrich Theodor Hopt; Frank Makowiec
Journal:  J Surg Oncol       Date:  2013-11-26       Impact factor: 3.454

5.  Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.

Authors:  David Cunningham; William H Allum; Sally P Stenning; Jeremy N Thompson; Cornelis J H Van de Velde; Marianne Nicolson; J Howard Scarffe; Fiona J Lofts; Stephen J Falk; Timothy J Iveson; David B Smith; Ruth E Langley; Monica Verma; Simon Weeden; Yu Jo Chua
Journal:  N Engl J Med       Date:  2006-07-06       Impact factor: 91.245

6.  TremelImumab and Durvalumab Combination for the Non-OperatIve Management (NOM) of Microsatellite InstabiliTY (MSI)-High Resectable Gastric or Gastroesophageal Junction Cancer: The Multicentre, Single-Arm, Multi-Cohort, Phase II INFINITY Study.

Authors:  Alessandra Raimondi; Federica Palermo; Michele Prisciandaro; Massimo Aglietta; Lorenzo Antonuzzo; Giuseppe Aprile; Rossana Berardi; Giovanni G Cardellino; Giovanni De Manzoni; Ferdinando De Vita; Massimo Di Maio; Lorenzo Fornaro; Giovanni L Frassineti; Cristina Granetto; Francesco Iachetta; Sara Lonardi; Roberto Murialdo; Elena Ongaro; Francesca Pucci; Margherita Ratti; Nicola Silvestris; Valeria Smiroldo; Andrea Spallanzani; Antonia Strippoli; Stefano Tamberi; Emiliano Tamburini; Alberto Zaniboni; Maria Di Bartolomeo; Chiara Cremolini; Carlo Sposito; Vincenzo Mazzaferro; Filippo Pietrantonio
Journal:  Cancers (Basel)       Date:  2021-06-07       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.